ArticleMolecular pharmacology2022

Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.

Sean A Misek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.